The relative importance of the two major inhibitors of fibrinolysis, α2-antiplasmin (α2-AP) and plasminogen activator inhibitor (PAI-1), were investigated using a simple microtitre plate system to study fibrin clot lysis in vitro. Cross-linked fibrin clots contained plasminogen and tissue plasminogen activator (t-PA) at concentrations close to physiological. Purified α2-AP and PAI-1 caused dose-dependent inhibition. All the inhibition due to normal plasma, either platelet-rich or poor, was neutralised only by antibodies to α2-AP. Isolated platelets, at a final concentration similar to that in blood, 2.5 × 108/ml, markedly inhibited clot lysis. This inhibition was neutralised only by antibodies to PAI-1. At the normal circulating ratio of plasma to platelets, α2-AP was the dominant inhibitor. When the platelet:plasma ratio was raised some 20-fold, platelet PAI-1 provided a significant contribution. High local concentrations of PAI-1 do occur in thrombi in vivo, indicating a role for PAI-1, complementary to that of α2-AP, in such situations.
References
1
Collen D.
On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
3
Hoylaerts M,
Rijken DC,
Lijnen HR,
Collen D.
Kinetics of the activation of plasminogen by human tissue-plasminogen activators. Role of fibrin. J Biol Chem 1982; 257: 2912-2919
7
Wiman B,
Collen D.
Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem 1977; 78: 19-26
9
Kruithof EKO,
Tran-Thang C,
Ransijin A,
Bachmann F.
Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
11
Declerck PJ,
Alessi MC,
Verstreken EKO,
Kruithof I,
Juhan-Vague I,
Collen D.
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzymelinked immunosorbent assay. Blood 1988; 71: 220-225
12
Sprengers ED,
Akkerman JWN,
Jansen BG.
Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemostas 1986; 55: 325-329
13
Simpson AJ,
Booth NA,
Moore NR,
Bennett B.
The platelet and plasma pools of plasminogen activator inhibitor PAI-1 vary independently in disease. Br J Haematol 1990; 75: 543-548
14
Kruithof EKO,
Gudinchet A,
Bachmann F.
Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemostas 1988; 59: 7-12
15
Chmielewska J,
Ranby M,
Wiman B.
Kinetics of the inhibition of plasminogen activators by the plasminogen activator inhibitor. Biochem J 1988; 251: 327-332
18
Wagner OF,
de Vries C,
Hohmann C,
Veerman H,
Pannekoek H.
Interaction between plasminogen activator inhibitor typel (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA) Binding of t-PA-PAI-1 complexes to fibrin mediated by both finger and kringle-2 domain of t-PA. J Clin Invest 1989; 84: 647-655
19
Keijer J,
Linders M,
van Zonneveld A-J,
Ehrlich HJ,
de Boer J-P,
Pannekoek H.
The interaction of plasminogen activator inhibitor 1 (PAI-1) with plasminogen activators (t-PA, u-PA) and fibrin: localization of interaction sites and physiological relevance. Blood 1991; 78: 401-409
21
de Fouw NJ,
de Jong YF,
Haverkate F,
Bertina RM.
The influence of thrombin and platelets on fibrin clot lysis rates in vitro: a study using a clot lysis system consisting of purified human proteins. Fibrinolysis 1988; 2: 235-244
22
Jones AJS,
Meunier AM.
A precise and rapid microtitre plate clot lysis assay: methodology, kinetic modelling and measurement of catalytic constants for plasminogen activation during fibrinolysis. Thromb Haemostas 1990; 64: 455-463
23
MacGregor IR,
Booth NA.
An enzyme-linked immunosorbent assay (ELISA) used to study the cellular secretion of endothelial plasminogen activator inhibitor (PAI). Thromb Haemostas 1988; 59: 68-72
32
Potter van LoonBJ,
Rijken DC,
Brommer EJP,
van der MaasAPC.
The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemostas 1992; 67: 101-105
33
Levi M,
Biemond BJ,
van Zonnevald A-J,
ten Cate JW,
Pannekoek H.
Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305-312
34
Reed GL,
Matsueda GR,
Haber E.
Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of α2-antiplasmin to fibrin. Thromb Haemostas 1992; 68: 315-320
